PMA device
Exablate 2000 MRI Guided Focused Ultrasound System
Insightec, Ltd. · Ultrasound, Hyperthermia, Cancer Treatment (LSY, Class III) · First FDA decision Dec 30, 2005, newest Dec 30, 2005Tumor ablationUterine fibroids and heavy menstrual bleeding
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
11
Naming "Exablate 2000"
MAUDE reports
0
Brand "Exablate 2000", since 2015
PubMed studies
24
Mentioning "Exablate 2000"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Exablate 2000 MRI Guided Focused Ultrasound System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EXABLATE 2000 MRI GUIDED FOCUSED ULTRASOUND SYSTEMPMA supplement
P040003-S001 · Decided Dec 30, 2005 · 127 days after receipt · Normal 180 Day Track No User Fee
Device type: Ultrasound, hyperthermia, cancer treatment (LSY) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hyperthermia for Treatment of CancerNational determinationOn the books110.1Updated Apr 17, 2020
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40168Wellpoint FederalUpdated Jul 14, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40179CGS Administrators, LLCUpdated Apr 17, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40193WPS Insurance CorporationUpdated Mar 12, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40189Palmetto GBAUpdated Mar 11, 2026
- Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Local determinationIn effectL40176Noridian Healthcare Solutions, LLCUpdated Mar 10, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Exablate 2000", any status and sponsor, newest update first.
Matthew BucknorAcademic, hospital or other
NCT04123535 · 5 participants · Start Jan 23, 2020 · Primary completion Apr 30, 2026
Device: ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) · For: Undifferentiated Pleomorphic Sarcoma
Sites: San Francisco, California
InSightecNot on our public-company list
NCT00131365 · 9 participants · Start Jan 2006 · Primary completion Jan 2009
Device: ExAblate 2000 · For: Leiomyoma
Sites: New York, New York
InSightecNot on our public-company list
NCT01091883 · 60 participants · Start May 2010 · Primary completion Jan 2019
Device: Exablate treatment · For: Bone Cancer; Bone Metastases; Pain
Sites: Taipei City, Taiwan
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Exablate 2000", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LSY
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Exablate 2000"[tiab]. The summary above synthesizes these.
- Sonoablation and application of MRI guided focused ultrasound in a preclinical model.
Zibly Z, Graves CA, Harnof S, et al. · J Clin Neurosci · 2014
- Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study.
Quinn SD, Vedelago J, Regan L, et al. · J Ther Ultrasound · 2013
- An optimum method for pulsed high intensity focused ultrasound treatment of large volumes using the InSightec ExAblate® 2000 system.
O'Neill BE, Karmonik C, Li KC · Phys Med Biol · 2010Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A clinical review of focused ultrasound ablation with magnetic resonance guidance: an option for treating uterine fibroids.
Hesley GK, Gorny KR, Henrichsen TL, et al. · Ultrasound Q · 2008Review
- An in-vivo investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth.
Ma CM, Chen X, Cvetkovic D, et al. · Med Phys · 2014Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Analysis and reduction of thermal dose errors in MRgFUS treatment.
Zucconi F, Colombo PE, Pasetto S, et al. · Phys Med · 2014Research Support, Non-U.S. Gov't
- Ultrasound focusing using magnetic resonance acoustic radiation force imaging: application to ultrasound transcranial therapy.
Hertzberg Y, Volovick A, Zur Y, et al. · Med Phys · 2010
- MR guided focused ultrasound: technical acceptance measures for a clinical system.
Gorny KR, Hangiandreou NJ, Hesley GK, et al. · Phys Med Biol · 2006Evaluation Study, Research Support, Non-U.S. Gov't
- Evaluation of mineral oil as an acoustic coupling medium in clinical MRgFUS.
Gorny KR, Hangiandreou NJ, Hesley GK, et al. · Phys Med Biol · 2007
- Magnetic resonance-guided focused ultrasound treatment of facet joint pain: summary of preclinical phase.
Harnof S, Zibly Z, Shay L, et al. · J Ther Ultrasound · 2014
- Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up.
Funaki K, Fukunishi H, Sawada K · Ultrasound Obstet Gynecol · 2009
- Initial evaluation of acoustic reflectors for the preservation of sensitive abdominal skin areas during MRgFUS treatment.
Gorny KR, Chen S, Hangiandreou NJ, et al. · Phys Med Biol · 2009Evaluation Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.